在瘤进展中,G蛋白合受体介导的免疫调节信号传递
Guang-Hong Qiu1, Bin Yu2, Mei Ma1
1Department of Oncology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, PR China.
概括
G蛋白结合受体 (GPCRs) 是癌症生长和通过调节免疫细胞传播的关键驱动因素. 向GPCRs为新型癌症免疫疗法提供了一个有希望的策略.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- G蛋白结合受体 (GPCRs) 在瘤进展和转移中起着关键作用.
- GPCRs在瘤微环境中显著影响免疫细胞功能.
研究的目的:
- 阐明GPCRs的免疫细胞作用及其在瘤进展中的信号传递.
- 通过免疫检查点调节检查GPCR参与免疫逃避.
- 审查针对GPCR向癌症疗法的临床试验,特别是与免疫疗法结合使用的临床试验.
主要方法:
- 对癌症免疫学中GPCRs的当前文献的综述.
- 在瘤微环境中分析GPCR信号通路.
- 检查针对GPCR向药物的临床试验数据.
主要成果:
- GPCRs是瘤生长,转移和免疫规避的组成部分.
- GPCRs调节免疫检查点蛋白,影响抗瘤免疫力.
- 针对GPCR的药物显示出潜力,特别是与免疫疗法相结合时.
结论:
- 了解GPCRs的免疫细胞功能,可以了解瘤进展.
- 向GPCRs代表了癌症免疫疗法的新且有前途的途径.
- 涉及GPCR抑制剂和免疫疗法的组合疗法可能会提高治疗疗效.
更多相关视频
相关概念视频
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Tumor Immunotherapy
504
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
504
Amplifying Signals via Enzymatic Cascade
8.4K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.4K
Receptor Downregulation in MVBs
2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.0K
TGF - β Signaling Pathway
7.3K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K


